Stefania Oliva, MD, GIMEMA, European Myeloma Network, Italy, discusses the findings of an analysis of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) in the FORTE trial (NCT02203643). The FORTE trial compared three treatment arms in patients with multiple myeloma: carfilzomib-lenalidomide-dexamethasone (KRd) or carfilzomib-cyclophosphamide-dexamethasone (KCd) induction prior to autologous stem-cell transplantation or 12 cycles of KRd only, before further randomization to KR or R maintenance. The results showed that pre-maintenance MRD-negative patients had a longer progression-free survival (PFS) and overall survival compared to MRD-positive patients, and that KR significantly prolonged PFS compared to R, regardless of pre-maintenance MRD status. A high degree of concordance was shown between MFC and NGS, with outcomes of patients determined MRD-negative by both techniques being similar. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.